{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:49:32Z","timestamp":1791226172379,"version":"4.1.0"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"vor","delay-in-days":36,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Veterinary Journal"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.tvjl.2020.105562","type":"journal-article","created":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T08:11:53Z","timestamp":1602144713000},"page":"105562","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Efficacy of pergolide for the management of equine pituitary pars intermedia dysfunction: A systematic review"],"prefix":"10.1016","volume":"266","author":[{"given":"R.C.","family":"Tatum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.M.","family":"McGowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.L.","family":"Ireland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tvjl.2020.105562_bib0005","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.nmd.2006.07.019","article-title":"Myopathy in horses with pituitary pars intermedia dysfunction (Cushing\u2019s disease)","volume":"16","author":"Aleman","year":"2006","journal-title":"Neuromusc. Disord."},{"key":"10.1016\/j.tvjl.2020.105562_bib0010","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1210\/endo-128-1-65","article-title":"The effect of acute exercise on the secretion of corticotropin-releasing factor, arginine vasopressin, and adrenocorticotropin as measured in pituitary venous blood from the horse","volume":"128","author":"Alexander","year":"1991","journal-title":"Endocrinology"},{"key":"10.1016\/j.tvjl.2020.105562_bib0015","first-page":"175","article-title":"Comparison of Vitex agnus castus extract and pergolide in treatment of Equine Cushing\u2019s syndrome","volume":"48","author":"Beech","year":"2002","journal-title":"Am. Assoc. Equine Pract."},{"key":"10.1016\/j.tvjl.2020.105562_bib0020","doi-asserted-by":"crossref","first-page":"715","DOI":"10.2460\/javma.235.6.715","article-title":"Evaluation of plasma ACTH, \u03b1-melanocyte-stimulating hormone, and insulin concentrations during various photoperiods in clinically normal horses and ponies and those with pituitary pars intermedia dysfunction","volume":"235","author":"Beech","year":"2009","journal-title":"J. Am. Vet. Med. Assoc."},{"key":"10.1016\/j.tvjl.2020.105562_bib0025","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2460\/javma.2003.223.93","article-title":"Demographic and clinical characteristics of geriatric horses: 467 cases (1989-1999)","volume":"223","author":"Brosnahan","year":"2003","journal-title":"J. Am. Vet. Med. Assoc."},{"key":"10.1016\/j.tvjl.2020.105562_bib0030","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.tvjl.2018.03.007","article-title":"Fecal strongyle egg counts in horses with suspected pre-clinical pituitary pars intermedia dysfunction before and after treatment with pergolide","volume":"235","author":"Christen","year":"2018","journal-title":"Vet. J."},{"key":"10.1016\/j.tvjl.2020.105562_bib0035","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.2042-3306.2011.00444.x","article-title":"Circannual variation in plasma adrenocorticotropic hormone concentrations in the UK in normal horses and ponies, and those with pituitary pars intermedia dysfunction","volume":"44","author":"Copas","year":"2012","journal-title":"Equine Vet. J."},{"key":"10.1016\/j.tvjl.2020.105562_bib0040","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2460\/javma.234.3.385","article-title":"Effects of compounding and storage conditions on stability of pergolide mesylate","volume":"234","author":"Davis","year":"2009","journal-title":"J. Am. Vet. Med. Assoc."},{"key":"10.1016\/j.tvjl.2020.105562_bib0045","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.domaniend.2014.02.004","article-title":"Influence of feeding status, time of the day, and season on baseline adrenocorticotropic hormone and the response to thyrotropin releasing hormone-stimulation test in healthy horses","volume":"48","author":"Diez de Castro","year":"2014","journal-title":"Domest. Anim. Endocrinol."},{"key":"10.1016\/j.tvjl.2020.105562_bib0050","first-page":"742","article-title":"Treatment with pergolide or cyproheptadine of pituitary pars intermedia dysfunction (Equine Cushing\u2019s Disease)","volume":"16","author":"Donaldson","year":"2002","journal-title":"J. Vet. Intern. Med."},{"key":"10.1016\/j.tvjl.2020.105562_bib0055","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/evj.12089","article-title":"Severe hypertriglyceridaemia in horses and ponies with endocrine disorders","volume":"46","author":"Dunkel","year":"2014","journal-title":"Equine Vet. J."},{"key":"10.1016\/j.tvjl.2020.105562_bib0060","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/eve.12160","article-title":"Pituitary pars intermedia dysfunction: diagnosis and treatment","volume":"26","author":"Durham","year":"2014","journal-title":"Equine Vet. Educ."},{"key":"10.1016\/j.tvjl.2020.105562_bib0065","first-page":"301","article-title":"Endocrine disease in aged horses","volume":"32","author":"Durham","year":"2016","journal-title":"Vet. Clin. N. Am.: Equine Pract."},{"key":"10.1016\/j.tvjl.2020.105562_bib0070","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1751-0147-50-6","article-title":"Circulating beta-endorphin, adrenocorticotrophic hormone and cortisol levels of stallions before and after short road transport: stress effect of different distances","volume":"50","author":"Fazio","year":"2008","journal-title":"Acta Vet. Scand."},{"key":"10.1016\/j.tvjl.2020.105562_bib0075","first-page":"523","article-title":"The welfare of animals used in science: how the \u201cThree Rs\u201d ethic guides improvements","volume":"50","author":"Fenwick","year":"2009","journal-title":"Can. Vet. J."},{"key":"10.1016\/j.tvjl.2020.105562_bib0080","first-page":"23","article-title":"Effective long-term treatment of equine pituitary pars intermedia adenomas with dopamine agonist","volume":"106","author":"Froin","year":"1998","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"10.1016\/j.tvjl.2020.105562_bib0085","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jevs.2013.11.001","article-title":"Comparison of insulin and glucose metabolism in horses with pituitary pars intermedia dysfunction treated versus not treated with pergolide","volume":"34","author":"Gehlen","year":"2014","journal-title":"J. Equine Vet. Sci."},{"key":"10.1016\/j.tvjl.2020.105562_bib0090","first-page":"E1","article-title":"Single-dose oral pharmacokinetics of pergolide mesylate in healthy adult mares","volume":"11","author":"Gehring","year":"2010","journal-title":"Vet. Ther.: Res. Appl. Vet. Med."},{"key":"10.1016\/j.tvjl.2020.105562_bib0095","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s007020200052","article-title":"Pergolide protects dopaminergic neurons in primary culture under stress conditions","volume":"109","author":"Gille","year":"2002","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.tvjl.2020.105562_bib0100","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3138\/jvme.1111.109R","article-title":"Searching the veterinary literature: a comparison of the coverage of veterinary journals by nine bibliographic databases","volume":"39","author":"Grindlay","year":"2012","journal-title":"J. Vet. Med. Educ."},{"key":"10.1016\/j.tvjl.2020.105562_bib0105","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1177\/030098589902700606","article-title":"Immunocytochemical demonstration of proopiomelanocortin-derived peptides in pituitary adenomas of the pars intermedia in horses","volume":"27","author":"Heinrichs","year":"1990","journal-title":"Vet. Pathol."},{"key":"10.1016\/j.tvjl.2020.105562_bib0110","first-page":"375","article-title":"Clinical presentation, diagnosis, and prognosis of chronic laminitis","volume":"15","author":"Herthel","year":"1999","journal-title":"Vet. Clin. N. Am.: Equine Pract."},{"key":"10.1016\/j.tvjl.2020.105562_bib0115","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/evj.13041","article-title":"Factors associated with survival, laminitis and insulin dysregulation in horses diagnosed with equine pituitary pars intermedia dysfunction","volume":"51","author":"Horn","year":"2019","journal-title":"Equine Vet. J."},{"key":"10.1016\/j.tvjl.2020.105562_bib0120","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1365-3164.2012.01080.x","article-title":"Comparison of hair follicle histology between horses with pituitary pars intermedia dysfunction and excessive hair growth and normal aged horses","volume":"24","author":"Inner\u00e5","year":"2013","journal-title":"Vet. Dermatol."},{"key":"10.1016\/j.tvjl.2020.105562_bib0125","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.2042-3306.2010.00145.x","article-title":"A cross-sectional study of geriatric horses in the United Kingdom. Part 1: Demographics and management practices","volume":"43","author":"Ireland","year":"2011","journal-title":"Equine Vet. J."},{"key":"10.1016\/j.tvjl.2020.105562_bib0130","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.tvjl.2018.03.002","article-title":"Epidemiology of pituitary pars intermedia dysfunction: a systematic literature review of clinical presentation, disease prevalence and risk factors","volume":"235","author":"Ireland","year":"2018","journal-title":"Vet. J."},{"key":"10.1016\/j.tvjl.2020.105562_bib0135","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1093\/ije\/dyi060","article-title":"Proper interpretation of non-differential misclassification effects: expectations vs observations","volume":"34","author":"Jurek","year":"2005","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.tvjl.2020.105562_bib0140","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.domaniend.2011.05.004","article-title":"The prevalence of endocrinopathic laminitis among horses presented for laminitis at a first-opinion\/referral equine hospital","volume":"41","author":"Karikoski","year":"2011","journal-title":"Domest. Anim. Endocrinol."},{"key":"10.1016\/j.tvjl.2020.105562_bib0145","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0007-1935(05)80084-3","article-title":"Equine Cushing\u2019s disease","volume":"149","author":"Love","year":"1993","journal-title":"Br. Vet. J."},{"key":"10.1016\/j.tvjl.2020.105562_bib0150","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.2460\/ajvr.2005.66.2065","article-title":"Systemic and pituitary pars intermedia antioxidant capacity associated with pars intermedia oxidative stress and dysfunction in horses","volume":"66","author":"McFarlane","year":"2005","journal-title":"Am. J. Vet. Res."},{"key":"10.1016\/j.tvjl.2020.105562_bib0155","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1365-2826.2005.01277.x","article-title":"Nitration and increased alpha-synuclein expression associated with dopaminergic neurodegeneration in equine pituitary pars intermedia dysfunction","volume":"17","author":"McFarlane","year":"2005","journal-title":"J. Neuroendocrinol."},{"key":"10.1016\/j.tvjl.2020.105562_bib0160","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.domaniend.2005.07.005","article-title":"Alpha-melanocyte stimulating hormone release in response to thyrotropin releasing hormone in healthy horses, horses with pituitary pars intermedia dysfunction and equine pars intermedia explants","volume":"30","author":"McFarlane","year":"2006","journal-title":"Domest. Anim. Endocrinol."},{"key":"10.1016\/j.tvjl.2020.105562_bib0165","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.arr.2007.02.001","article-title":"Advantages and limitations of the equine disease, pituitary pars intermedia dysfunction as a model of spontaneous dopaminergic neurodegenerative disease","volume":"6","author":"McFarlane","year":"2007","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.tvjl.2020.105562_bib0170","first-page":"93","article-title":"Equine pituitary pars intermedia dysfunction","volume":"27","author":"McFarlane","year":"2011","journal-title":"Vet. Clin. N. Am.: Equine Pract."},{"key":"10.1016\/j.tvjl.2020.105562_bib0175","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/jvp.12339","article-title":"Pharmacokinetic and pharmacodynamic properties of pergolide mesylate following long-term administration to horses with pituitary pars intermedia dysfunction","volume":"40","author":"McFarlane","year":"2017","journal-title":"J. Vet. Pharmacol. Ther."},{"key":"10.1016\/j.tvjl.2020.105562_bib0180","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.2042-3306.2012.00578.x","article-title":"Prevalence, risk factors and clinical signs predictive for equine pituitary pars intermedia dysfunction in aged horses","volume":"45","author":"McGowan","year":"2013","journal-title":"Equine Vet. J."},{"key":"10.1016\/j.tvjl.2020.105562_bib0185","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.2042-3306.2012.00575.x","article-title":"Evaluation of basal plasma \u03b1-melanocyte-stimulating hormone and adrenocorticotrophic hormone concentrations for the diagnosis of pituitary pars intermedia dysfunction from a population of aged horses","volume":"45","author":"McGowan","year":"2013","journal-title":"Equine Vet. J."},{"key":"10.1016\/j.tvjl.2020.105562_bib0190","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jclinepi.2016.01.021","article-title":"PRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement","volume":"75","author":"McGowan","year":"2016","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.tvjl.2020.105562_bib0195","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1136\/vr.149.14.417","article-title":"Sentinel practice-based survey of the management and health of horses in northern Britain","volume":"149","author":"Mellor","year":"2001","journal-title":"Vet. Rec."},{"key":"10.1016\/j.tvjl.2020.105562_bib0200","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1210\/endo-123-3-1598","article-title":"Equine Cushing\u2019s disease: differential regulation of \u03b2-endorphin processing in tumors of the intermediate pituitary","volume":"123","author":"Millington","year":"1988","journal-title":"Endocrinology"},{"key":"10.1016\/j.tvjl.2020.105562_bib0205","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.tvjl.2020.105562_bib0210","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1136\/vr.139.2.41","article-title":"Pergolide treatment for Cushing\u2019s syndrome in a horse","volume":"139","author":"Mu\u00f1oz","year":"1996","journal-title":"Vet. Rec."},{"issue":"S30","key":"10.1016\/j.tvjl.2020.105562_bib0215","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/j.2042-3306.1999.tb05286.x","article-title":"Plasma adrenocorticotropin, cortisol and catecholamines response to various exercises","volume":"31","author":"Nagata","year":"1999","journal-title":"Equine Vet. J."},{"key":"10.1016\/j.tvjl.2020.105562_bib0220","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1210\/endo-110-4-1430","article-title":"Equine Cushing\u2019s disease: plasma immunoreactive proopiolipomelanocortin peptide and cortisol levels basally and in response to diagnostic tests","volume":"110","author":"Orth","year":"1982","journal-title":"Endocrinology"},{"key":"10.1016\/j.tvjl.2020.105562_bib0225","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1111\/j.1939-1676.2011.00784.x","article-title":"Computed tomographic findings in the pituitary gland and brain of horses with Pituitary Pars Intermedia Dysfunction","volume":"25","author":"Pease","year":"2011","journal-title":"J. Vet. Intern. Med."},{"key":"10.1016\/j.tvjl.2020.105562_bib0230","doi-asserted-by":"crossref","first-page":"679","DOI":"10.2746\/042516402776250333","article-title":"Plasma adrenocorticotropin (ACTH) concentrations and clinical response in horses treated for equine Cushing\u2019s disease with cyproheptadine or pergolide","volume":"34","author":"Perkins","year":"2002","journal-title":"Equine Vet. J."},{"key":"10.1016\/j.tvjl.2020.105562_bib0235","first-page":"154","article-title":"Low-dose pergolide mesylate treatment for equine hypophyseal adenomas","volume":"41","author":"Peters","year":"1995","journal-title":"Am. Assoc. Equine Pract."},{"key":"10.1016\/j.tvjl.2020.105562_bib0240","doi-asserted-by":"crossref","first-page":"598","DOI":"10.21836\/PEM20100416","article-title":"Equine Cushing\u2019s syndrome: the effects of long-term therapy with pergolide","volume":"26","author":"Pongratz","year":"2010","journal-title":"Pferdeheilkunde"},{"issue":"S44","key":"10.1016\/j.tvjl.2020.105562_bib0245","first-page":"19","article-title":"Effects of pergolide mesylate on plasma adrenocorticotropic hormone concentration in horses with pituitary pars intermedia dysfunction","volume":"45","author":"Rendle","year":"2013","journal-title":"Equine Vet. J."},{"key":"10.1016\/j.tvjl.2020.105562_bib0250","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/jvim.12489","article-title":"Investigation of single and paired measurements of adrenocorticotropic hormone for the diagnosis of pituitary pars intermedia dysfunction in horses","volume":"29","author":"Rendle","year":"2015","journal-title":"J. Vet. Intern. Med."},{"issue":"S52","key":"10.1016\/j.tvjl.2020.105562_bib0255","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/evj.16_13008","article-title":"Efficacy of a novel palatable pergolide paste formulation for the treatment of pituitary pars intermedia dysfunction (PPID) in ponies","volume":"50","author":"Rendle","year":"2018","journal-title":"Equine Vet. J."},{"key":"10.1016\/j.tvjl.2020.105562_bib0260","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.domaniend.2019.01.008","article-title":"Pharmacokinetics and pharmacodynamics of pergolide mesylate after oral administration in horses with pituitary pars intermedia dysfunction","volume":"68","author":"Rendle","year":"2019","journal-title":"Domest. Anim. Endocrinol."},{"key":"10.1016\/j.tvjl.2020.105562_bib0265","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/1356389008097871","article-title":"Testing methodological guidance on the conduct of narrative synthesis in systematic reviews: effectiveness of interventions to promote smoke alarm ownership and function","volume":"15","author":"Rodgers","year":"2009","journal-title":"Evaluation"},{"key":"10.1016\/j.tvjl.2020.105562_bib0270","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1111\/j.1939-1676.2012.00932.x","article-title":"Diagnostic frequency, response to therapy, and long term prognosis among horses and ponies with pituitary pars intermedia dysfunction, 1993-2004","volume":"23","author":"Rohrbach","year":"2012","journal-title":"J. Vet. Intern. Med."},{"key":"10.1016\/j.tvjl.2020.105562_bib0275","first-page":"22","article-title":"The Michigan Cushing\u2019s project","volume":"47","author":"Schott","year":"2001","journal-title":"Equine Pract."},{"key":"10.1016\/j.tvjl.2020.105562_bib0280","first-page":"237","article-title":"Pituitary pars intermedia dysfunction: Equine Cushing\u2019s disease","author":"Schott","year":"2002","journal-title":"Vet. Clin. N. Am.: Equine Pract."},{"key":"10.1016\/j.tvjl.2020.105562_bib0285","series-title":"Proceedings of the 60th Annual Convention of the American Association of Equine Practitioners","first-page":"329","article-title":"Long-term response of equids with pituitary pars intermedia dysfunction to treatment with pergolide","author":"Schott","year":"2014"},{"key":"10.1016\/j.tvjl.2020.105562_bib0290","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1023\/B:VERC.0000045368.38959.8b","article-title":"Equine cushing-like syndrome: diagnosis and therapy in two cases","volume":"28","author":"Sgorbini","year":"2004","journal-title":"Vet. Res. Commun."},{"key":"10.1016\/j.tvjl.2020.105562_bib0295","first-page":"254","article-title":"Stability of pergolide mesylate oral liquid at room temperature","volume":"13","author":"Shank","year":"2009","journal-title":"Int. J. Pharm. Compd."},{"key":"10.1016\/j.tvjl.2020.105562_bib0300","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1751-0813.2012.00997.x","article-title":"Case series of equine pituitary pars intermedia dysfunction in a tropical climate","volume":"90","author":"Spelta","year":"2012","journal-title":"Aust. Vet. J."},{"key":"10.1016\/j.tvjl.2020.105562_bib0305","first-page":"274","article-title":"Comparison of pharmaceutical equivalence for compounded preparations of pergolide mesylate","volume":"56","author":"Stanley","year":"2010","journal-title":"Proceedings of the 56th Annual Convention of the American Association of Equine Practitioners"},{"key":"10.1016\/j.tvjl.2020.105562_bib0310","first-page":"A16","article-title":"Cortisol and ACTH concentrations in ill horses throughout 6 days of hospitalisation","volume":"20","author":"Towns","year":"2010","journal-title":"J. Vet. Emerg. Crit. Care"},{"key":"10.1016\/j.tvjl.2020.105562_bib0315","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/S0140-6736(04)15945-X","article-title":"Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease","volume":"363","author":"Van Camp","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.tvjl.2020.105562_bib0320","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jevs.2008.12.006","article-title":"Correlation of plasma insulin concentration with laminitis score in a field study of equine Cushing\u2019s disease and equine metabolic syndrome","volume":"29","author":"Walsh","year":"2009","journal-title":"J. Equine Vet. Sci."},{"key":"10.1016\/j.tvjl.2020.105562_bib0325","first-page":"220","article-title":"Equine Cushing\u2019s Disease and the long-term treatment with oral pergolide mesylate","author":"Watson","year":"1998","journal-title":"The 18th Annual Proceedings of the American College of Veterinary Internal Medicine 16"},{"key":"10.1016\/j.tvjl.2020.105562_bib0330","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.prevetmed.2016.07.011","article-title":"Prevalence, survival analysis and multimorbidity of chronic diseases in the general veterinarian-attended horse population of the UK","volume":"131","author":"Welsh","year":"2016","journal-title":"Prev. Vet. Med."},{"key":"10.1016\/j.tvjl.2020.105562_bib0335","first-page":"41","article-title":"Equine Cushing\u2019s syndrome \u2013 retrospective study of twenty four cases and response to medication","volume":"34","author":"Williams","year":"1995","journal-title":"Br. Equine Vet. Assoc. Congr. Proc."},{"key":"10.1016\/j.tvjl.2020.105562_bib0340","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1210\/endo-110-3-941","article-title":"Proopiolipomelanocortin peptides in normal pituitary, pituitary tumor, and plasma of normal and Cushing's horses","volume":"110","author":"Wilson","year":"1982","journal-title":"Endocrinology"}],"container-title":["The Veterinary Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090023320301398?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090023320301398?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T18:30:16Z","timestamp":1761071416000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1090023320301398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":68,"alternative-id":["S1090023320301398"],"URL":"https:\/\/doi.org\/10.1016\/j.tvjl.2020.105562","relation":{},"ISSN":["1090-0233"],"issn-type":[{"value":"1090-0233","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of pergolide for the management of equine pituitary pars intermedia dysfunction: A systematic review","name":"articletitle","label":"Article Title"},{"value":"The Veterinary Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tvjl.2020.105562","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"105562"}}